Transcript Folie 1 - Rehaut Tempus Project

The name of the company describes our overarching aim:
To explain what genes do.
The logo nicely symbolizes how different scientific disciplines
may come together to effect a cross-fertilization of concepts
thereby yielding new insights: biology, chemistry, computer
sciences and mathematics combining together to generate new
theories and applications for future health research.
GeneXplain GmbH has been founded in April 2010 and is based in
Wolfenbüttel, Germany. The company aims at providing a comprehensive
set of computational tools supporting the complete drug development
pipeline from the statistical evaluation of high-throughput data, their
biological interpretation, identification of potential target to the prediction
of most promising lead structures.
Founders:
Prof. Dr. Edgar Wingender
Chief Executive Officer
It is Edgar's task to develop visions for the still
young company, implement them in the
company's strategic plans and organize the
company accordingly.
Dr. Alexander Kel
Chief Scientific Officer
Alexander is the major driving force behind
geneXplain's science and technology. It is his
task to let innovative products and services
materialize from new ingenious concepts.
Vision and Mission
It is geneXplain's mission to provide the computational
methodology required to achieve this goal of "personalized
pharmacogenomics".
We
wish
to
help
academic
researchers in their daily work with easy-to-use tools that
are compatible with the low-budget requirements of most
academic groups. At the same time, we shall provide highend
technology
platforms
to
fulfil
bioinformatics
requirements to industrial standards. Finally, we intend to
offer partnerships for research and training in the area of
our expertise.
The main aim is to provide a comprehensive platform of
bioinformatics, cheminformatics and systems biological
tools for personalized medicine and pharmacogenomics
Systems approaches will transform the way drugs are developed …
that will target multiple components of networks and pathways
perturbed in diseases.
They will enable medicine to become predictive, personalized,
preventive and participatory.
Products
GeneXplain Platform
Integrated and comprehensive
workflow management
including gene regulatory
modules, networks and
simulations
We are distributors of
In Silico Molecular Cloning (IMC)
Genome Traveler
handling large-scale genome data
PASS, PharmaExpert, GUSAR
predicting biological activities of
drug-like compounds
The geneXplain platform is an online toolbox and workflow
management system for a broad range of bioinformatic and
systems biology applications.
The key features of the geneXplain platform 1.0.0 include:
• A variety of modules or (“Bricks”) for bioinformatics and systems biology
• Predefined workflows
• Analysis and interpretation of high throughput biological data
• Pathway analysis and identification of causative biomarkers and drug
targets
• Working with any gene or protein list
• Analysis of raw microarray data of different experimental platforms
• Constructing new workflows by easy-to-use graphical programming
• Simulations and parameter optimization
• Incorporating customized scripts within the platform
• Toolkit to incorporate new bricks from external developers
• Easy-to-follow examples, comprehensive User Guide and Help files.
GeneXplain Integrated Workflow
From patient data to personalized pharmacological agents
Patient 1
Patient 2
Bioinformatics : Patient-specific
regulatory modules, transcription factors
Systems Biology: Patient-specific
networks, potential drug targets and
their ligands
Cheminformatics
Patient-specific pharmacological agents
…
Patient N
Integrated Workflow of Bioinformatics, Systems Biological
and Cheminformatics Tools
…
…
SAR/QSAR
Cheminformatics
Biological activities of
the compounds
Systems Biology
Network analysis and
simulation, potential
drug targets
Bioinformatics
Regulatory modules,
transcription factors
Example of the study:
geneXplain platform
case study
breast cancer
EU FP6 project ‘Net2Drug’
Case study: FP6 project ‘Net2Drug’
RITA-treated MCM7 breast cancer cell line
Prosurvival genes are
repressed at high
concentrations of Rita, but
not at low concentrations.
MEPCE
1
PA2G4
E2F1
0.8
HMGA1
0.6
UBE2M
TUBB3
0.4
CTRL
CBR3
0.2
TAGLN2
HRAS
0
0
-0.2
-0.4
-0.6
2
4
6
8
10
12
14
16
18
20
22
24
TRIM28
POMZP3
SARS2
CNOT3
MGAT1
SLC2A4RG
-0.8
-1
RPS6KA4
PKP3
C11orf51
Aim was to find
complementary
compounds repressing
prosurvival genes at low
concentrations.
Molecular mechanisms of Rita action and potential
target proteins for a complementary compound
PI3-kinase
PASS & PharmaExpert tools were applied:
selection of several structures with multi-target actions
PASS & PharmaExpert predictions
allowed to select compounds for experimental testing
24 mln chemical compounds from ChemNavigator
library
About 335,000 compounds with predicted
antineoplastic activity were identified at probability
cutoff > 50%
64 compounds with multi-target action were selected,
considering the targets predicted by the protein
network analysis
11 samples from ChemNavigator were tested at
Karolinska Institute (Stockholm, Sweden)
2 compounds were confirmed by apoptosis test
geneXplain GmbH
Am Exer 10b
D-38302 Wolfenbüttel,
Germany
office: +49-5331-9450434
e-mail
[email protected]
www.genexplain.com